WeVote
Log In

Bill

Bill

HF 802

A bill for an act relating to the right to try Act.

2025-2026 Regular Session

HF 802 addresses Iowa's Right to Try Act allowing terminally ill patients access to unapproved experimental treatments, though the bill was withdrawn after amendments and substitution with SF 233.

Withdrawn.
#diseases #medicalcare #rights
0
WeVote Research Nonpartisan
Bill Summary · HF 802

Legislative bill overview

HF 802 relates to Iowa's Right to Try Act, legislation that typically permits terminally ill patients to access experimental drugs, biologics, and devices not yet approved by the FDA. The bill was introduced in early March 2025 but was withdrawn on March 20 after amendments were adopted and a Senate file (SF 233) was substituted, suggesting significant revisions or a shift to parallel legislation.

Why is this important

Right to Try laws balance patient autonomy and hope against regulatory safety frameworks designed to protect public health. These laws directly affect terminally ill Iowans' access to potentially life-saving treatments and raise questions about informed consent, liability protections for manufacturers, and how states regulate pharmaceuticals when federal approval is unavailable.

Potential points of contention

  • Liability and manufacturer protection: How much legal immunity should companies have when providing unapproved treatments, and who bears responsibility if patients are harmed?
  • Balance with FDA authority: Whether state Right to Try laws should override or complement federal regulatory oversight of drug safety and efficacy
  • Access equity: Ensuring economically disadvantaged patients can access experimental treatments without cost barriers that create a two-tiered system

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.